111374-21-1
111374-21-1 結(jié)構(gòu)式
基本信息
2-Pyrazinecarboxamide, 6-(1-pyrrolidinyl)-N-2H-tetrazol-5-yl-
N-(1H-Tetrazol-5-yl)-6-(1-pyrrolidinyl)pyrazine-2-carboxamide
6-(1-Pyrrolidinyl)-N-(1H-tetrazol-5-yl)pyrazine-2-carboxamide
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-U00133 | 111374-21-1 HSR6071 | 111374-21-1 | 1mg | 1200元 |
| 2026/06/05 | HY-U00133 | 111374-21-1 HSR6071 | 111374-21-1 | 5mg | 3000元 |
| 2026/06/05 | HY-U00133 | 111374-21-1 HSR6071 | 111374-21-1 | 10mg | 4800元 |
常見問題列表
The experimental asthma caused by IgE antibody in rats is inhibited by HSR-6071 (0.01-0.1 mg/kg; i.v.) in a dose-dependent manner. The bronchoconstriction mediated by IgE or IgG antibody in guinea-pigs is also prevented by HSR-6071 (0.3, 1,3 mg/kg; i.v.). HSR-6071 inhibits cyclic AMP phosphodiesterase activity and produces relaxation of the guinea-pig isolated trachea.
HSR-6071 inhibits the IgE-mediated histamine release with an IC
50
of 0.46 nM. HSR-6071 is effective not only by i.v. but also by p.o. administration on the IgE mediated PCA in rats. The most potent inhibition with HSR-6071 is observed when it is given p.o. 5 min before the antigen challenge, indicating the rapid absorption of HSR-6071 through the gastrointestinal tract.